Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
Carbamazepine and oxcarbazepine are potent modulators of metabolic enzymes. Hence, potential drug-drug interactions (DDIs) may occur between these two drugs and antiretrovirals. Here, we aimed to assess the relevance of these DDIs in real-life clinical settings. Patients treated concomitantly with carbamazepine or oxcarbazepine and antiretrovirals for at least three months were considered. Data on therapeutic drug monitoring (TDM) of both antiepileptic and antiretrovirals as trough concentrations were collected. HIV-infected patients not concomitantly treated with antiepileptic drugs and who underwent TDM for antiretrovirals in the previous two years were considered as controls. Eleven HIV-positive patients prescribed carbamazepine or oxcarbazepine were identified. All the TDM evaluations for carbamazepine and oxcarbazepine resulted were within the therapeutic ranges. TDM results of darunavir measured in these patients were comparable with values usually measured in the control group. Conversely, the trough concentrations for atazanavir and dolutegravir demonstrated significantly lower values when compared with values usually measured in HIV-infected patients not treated with antiepileptic drugs (190±91 vs. 546±380 ng/mL; -65%, p<0.001; 191±78 vs. 1096±510 ng/mL; -83%, p<0.001, respectively). Co-administration of carbamazepine or oxcarbazepine with atazanavir or dolutegravir should be avoided owing to the potential risk of virological failure; in case of these two drugs, the adoption of TDM is strongly advisable, eventually combining with increased antiretroviral doses.